Dorzopt, eye drops 2% 5 ml

A local carbohydrase inhibitor, an anti-glaucoma drug. Reduces intraocular fluid secretion by slowing down the formation of hydrocarbonate with subsequent weakening of sodium and water transport. It does not cause accommodation spasm, miosis, hemeralopia.

Pharmacokinetics

It penetrates the eye mainly through the cornea (to a lesser extent through the sclera or limbus). Systemic absorption is low. After entering the blood, it quickly penetrates into red blood cells containing a significant amount of carboanhydrase II.

The binding to plasma proteins is 33%. It is transformed into N-desethylated metabolite, which is less active with respect to carboanhydrase II, but is able to block carboanhydrase I. With long-term use, it cumulates in erythrocytes.

Extracted by the kidneys unchanged and as metabolites. After withdrawal, the fast phase of excretion is followed by a slow phase caused by gradual release of the drug from the red blood cells, with a half-life (T _1/2 ) of about 4 months.

Indications

Active ingredient

Composition

The eye drops are 2% clear, colorless.

Associates:

Hyethylose,

Mannitol,

Citric acid monohydrate,

sodium hydroxide,

benzalkonium chloride,

purified water.

How to take, the dosage

Push 1 drop into the conjunctival sac of the affected eye 3 times a day.

In combination with beta-adrenoblockers for local use – 1 drop 2 times a day.

If more than one topical ophthalmic drug is used in treatment, it is administered at 10-minute intervals.

Interaction

Antiglaucoma drugs (beta-adrenoblockers, pilocarpine, dipivefrine, carbachol) increase the effect of dorzolamide.

Concomitant use with acetazolamide increases the risk of systemic side effects.

The toxicity may be increased with high doses of acetylsalicylic acid.

Special Instructions

The preservative benzalkonium chloride contained in the drug may be adsorbed by soft contact lenses, causing eye irritation and toxic effects. The drug should only be used after removing the contact lenses. Contact lenses shall be inserted not earlier than 15 min after dosing.

Potassium, serum electrolytes and blood pH should be monitored.

Elderly patients may be more sensitive to dorzolamide, so this category of patients may require dose reduction.

Impact on ability to drive vehicles and other mechanisms requiring high concentration

When taking this medicine, caution must be exercised while driving motor transport and engaging in other potentially dangerous activities requiring high concentration and quick psychomotor reactions.

Contraindications

With caution:

Side effects

Topical

Burning, paresthesias, itching in the eyes, lacrimation, blurred vision, eyelid irritation and swelling, conjunctivitis, superficial pitting keratitis, blepharitis, photophobia.

Rarely, iridocyclitis, increased corneal thickness, allergic reactions; hypotension of the eye, retinal detachment in patients after antiglaucomatous surgery.

Systemic

Mouth bitterness, nausea, headache, asthenia, nephrourolithiasis, erythema malignant exudative (Stevens-Johnson syndrome), toxic epidermal necrolysis (Lyell syndrome), agranulocytosis, aplastic anemia, skin rash.

Overdose

Symptoms: water-electrolyte metabolism disorders, acidosis, CNS disorders.

Treatment: symptomatic therapy is carried out. Electrolyte levels (especially potassium) and blood pH should be monitored.

Pregnancy use

Dorzopt is contraindicated in pregnancy, lactation and childhood.

Similarities